Abstract
Potassium channels form highly K+ ion-selective pores in the plasma membrane of excitable cells. Voltagegated potassium (Kv) channels open in response to membrane depolarization to allow rapid diffusion of K+ ions out of the cell, thus repolarizing the cell to restore a negative resting membrane potential. Inherited mutations in Kv channel genes produce abnormal cellular repolarization and cause diseases of excitable tissues. Small molecule interactions with Kv channels can cause similar pathologies. During the last decade of research into Kv channels and associated diseases - termed ‘channelopathies’ - we have begun to understand Kv channel function and dysfunction at the molecular level. In this review, the molecular mechanisms of Kv channelopathies are discussed, with particular emphasis on the overlap between inherited and acquired disease, and the drive towards novel channel-targeted therapies.
Keywords: Arrhythmia, hERG, IKr, IKs, KCNE, KCNQ1, Kv1.5, MinK, MiRP1
Current Pharmaceutical Design
Title: Molecular Mechanisms of Cardiac Voltage-Gated Potassium Channelopathies
Volume: 12 Issue: 28
Author(s): Geoffrey W. Abbott
Affiliation:
Keywords: Arrhythmia, hERG, IKr, IKs, KCNE, KCNQ1, Kv1.5, MinK, MiRP1
Abstract: Potassium channels form highly K+ ion-selective pores in the plasma membrane of excitable cells. Voltagegated potassium (Kv) channels open in response to membrane depolarization to allow rapid diffusion of K+ ions out of the cell, thus repolarizing the cell to restore a negative resting membrane potential. Inherited mutations in Kv channel genes produce abnormal cellular repolarization and cause diseases of excitable tissues. Small molecule interactions with Kv channels can cause similar pathologies. During the last decade of research into Kv channels and associated diseases - termed ‘channelopathies’ - we have begun to understand Kv channel function and dysfunction at the molecular level. In this review, the molecular mechanisms of Kv channelopathies are discussed, with particular emphasis on the overlap between inherited and acquired disease, and the drive towards novel channel-targeted therapies.
Export Options
About this article
Cite this article as:
Abbott W. Geoffrey, Molecular Mechanisms of Cardiac Voltage-Gated Potassium Channelopathies, Current Pharmaceutical Design 2006; 12 (28) . https://dx.doi.org/10.2174/138161206778522065
DOI https://dx.doi.org/10.2174/138161206778522065 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antiphospholipid Syndrome as a Neurological Disease
Current Rheumatology Reviews Anticonvulsant and Antitubercular Activities of 6-Phenyl/Biphenyl-4-yl-2- [2-(pyridin-2-ylamino)-ethyl]- and 6-(Biphenyl-4yl)-2-(2N-subtituted amin- 1-yl)-ethyl derivatives of 4,5-dihydropyridazin-3(2H)-one
Letters in Drug Design & Discovery Early Age of Migraine Onset is Independently Related to Cognitive Decline and Symptoms of Depression Affect Quality of Life
Current Neurovascular Research G Protein-Activated Inwardly Rectifying Potassium Channels as Potential Therapeutic Targets
Current Pharmaceutical Design Modulation of the TRPV1 Channel: Current Clinical Trials and Recent Patents with Focus on Neurological Conditions
Recent Patents on CNS Drug Discovery (Discontinued) Importance of ABC Transporters in Drug Development
Current Pharmaceutical Design A Case of Topiramate-Induced Epistaxis
Current Drug Safety Foreword
Current Topics in Medicinal Chemistry Pharmacological Targeting of Neuronal Kv7.2/3 Channels: A Focus on Chemotypes and Receptor Sites
Current Medicinal Chemistry Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients
Current Medicinal Chemistry Ifenprodil, a Novel NMDA Receptor Antagonist : Site and Mechanism of Action
Current Drug Targets Genetic Polymorphisms of ATP-Binding Cassette Transporters ABCB1 and ABCC2 and their Impact on Drug Disposition
Current Drug Targets HIV-1 Reactivation Induced by Apicidin Involves Histone Modification in Latently Infected Cells
Current HIV Research Pathophysiology of Status Epilepticus Induced by Pilocarpine
Central Nervous System Agents in Medicinal Chemistry Functional Neuroimaging in Memory and Memory Disturbances
Current Medical Imaging Elaboration and Validation of HPLC/DAD Method for Quality Control of Products Containing Cannabidiol
Current Pharmaceutical Analysis The Menstrual Cycle and Drug Metabolism
Current Drug Metabolism Editorial [Hot Topic: New Mechanisms of Neuronal Injury and Neuroprotection (Guest Editor: Weihai Ying)]
Current Drug Targets Is a "Mitochondrial Psychiatry" in the Future? A Review
Current Psychiatry Reviews Inquiries into the Biological Significance of Transmembrane AMPA Receptor Regulatory Protein (TARP) γ−8 Through Investigations of TARP γ−8 Null Mice§
CNS & Neurological Disorders - Drug Targets